Cardio Diagnostics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Follow-Up Questions
What is Cardio Diagnostics Holdings Inc (CDIO)'s P/E Ratio?
The P/E ratio of Cardio Diagnostics Holdings Inc is N/A
What is the price performance of CDIO stock?
The current price of CDIO is 3.88, it has increased 0.4% in the last trading day.
What are the primary business themes or industries for Cardio Diagnostics Holdings Inc?
Cardio Diagnostics Holdings Inc belongs to Biotechnology industry and the sector is Health Care
What is Cardio Diagnostics Holdings Inc market cap?
Cardio Diagnostics Holdings Inc's current market cap is $6.8
Is Cardio Diagnostics Holdings Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Cardio Diagnostics Holdings Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
